ISO/HL7 27953 Specification: Individual Case Safety Report (ICSR) Release 2 Lise Stevens Data Standards Project Manager FDA CBER/ADRM Bioinformatics Support.

Slides:

Advertisements

Similar presentations

© 2011 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International.

Advertisements

HL7 January Working Group Meeting

Joint TC Meeting: EHR – RCRIM RCRIM Overview HL7 Working Group Meeting January, 2007 Presented by: Ed Tripp Program Director, eSubmissions Abbott (RCRIM.

17 September 2007ISO TC215 WG6 Brisbane1 Identification of Medicinal Products & Pharmacovigilance Task Forces.

Quality Label and Certification Processes Vienna Summit 11 April 2014 Karima Bourquard Director of Interoperability IHE-Europe.

Electronic Common Technical Document (eCTD) Update Jon Clark ICH M2 Deputy Topic Leader January 21, 2003.

Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

History of FDA and Related Regulatory Agencies

Introduction to Regulation

Knowledge Update Clinical documentation: from preclinical studies to drug registration Split, 12 September 2008.

CDRH Software Regulation

Unique Device Identification (UDI): Implementation and Adoption Leslie M Tompkins, PhD FDA, Center for Devices and Radiological Health UDI Lead, Standards.

Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

Requirements for Standardized Study Data: Update on Guidance Ron Fitzmartin, PhD, MBA Data Standards Program Office of Strategic Programs Center for Drug.

Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 

Justina A. Molzon, MS Pharm, JD

HL7 Study Data Standards Project Crystal Allard CDER Office of Computational Science Food and Drug Administration February 13,

Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.

ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.

Second Annual Japan CDISC Group (JCG) Meeting 28 January 2004 Julie Evans Director, Technical Services.

1 RCRIM Vocab-BRIDG Session Wednesday, Session Q2 19 September 2007.

*The views expressed in this presentation are those of the presenter’s and do not necessarily represent the views of the U.S. Food and Drug Administration.

1 CONSENSUS STANDARDS OIVD WORKSHOP April 22-23, 2003 Rockville MD Ginette Y. Michaud, M.D. OIVD.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

Communication of Drug Safety Information Food and Drug Administration Center for Drug Evaluation & Research Public Hearing December 8, 2005.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

Implementation of the CTD: CBER’S Perspective May 8, 2001 Joan Wilmarth Blair, M.A. International Affairs Advisor CBER/FDA May 8, 2001 Joan Wilmarth Blair,

Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.

Utah Life Science Summit Nov Phil Triolo, PhD RAC President, Phil Triolo and Associates LC.

CTD Dossier Preparation K. Srikantha Reddy Sr

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

FDA ICH Public Meeting 5630 Fishers Lane, Rockville, MD May 8, :30 am -- 2:00 pm Implementation of the CTD Update-Issues-Next Steps Justina A. Molzon,

FDA Standards Development and Implementation Randy Levin, M.D. Director, Office of Information Management Center for Drug Evaluation and Research Food.

FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.

CDISC – 17/12/2012 Carine Javierre Nathalie SABIN.

Update on Current FDA Labeling Initiatives Iris P. Masucci, PharmD, BCPS Center for Drug Evaluation and Research FDA November 16, 2006 Pediatric Advisory.

ICH Quality Topics Update

1 COMMON TECHNICAL DOCUMENT / ORIGIN OF CTD… ICH EWG CTD WAS OFFICIALLY SIGNED OFF IN NOVEMBER 2000, AT 5 TH ICH CONFERENCE; SAN DIEGO,CALIFORNIA.

JMAFF (Chair of Biologicals Quality Monitoring EWG)

VICH Guidelines: Stability Testing of New Veterinary Drug Substances and Medicinal Products Mai Huynh U.S. FDA Center for Veterinary Medicine Washington.

Development and Harmonization VICH5 November 29, 2015 VICH Electronic Standards Implementation Margarita Brown, DVM MS, Chair FDA Center for Veterinary.

VICH General Principles and current update of VICH Outreach Forum activity 1.

© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.

Regulated Product Submission Eileen M. Girten, MS i3 Statprobe 1DIA Education SIAC.

Auditing ISO Nancy Pasquan November Introductions I am….. You are….. And we are here to discuss: Auditing ISO Quality Systems for Medical.

Submission Standards: The Big Picture Gary G. Walker Associate Director, Programming Standards, Global Data Solutions, Global Data Management.

1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.

Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.

VICH General Principles and

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

CTD Content Management

The Information Professional’s Role in Product Safety

ICH-GCP Avinash Kondawar M. Pharm Lead CRA

Clinical Trials — A Closer Look

Michelle Limoli, Pharm.D.

Veterinary Pharmacovigilance Discussion

American Society for Quality Region 5 Quality Conference

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

The Lifecycle of Pharmaceutical products

Guideline prepared by the Veterinary Harmonisation Group

HOW TO FULFILL STATUTORY REQUIREMENTS ON PRODUCT RELATED HEALTH INFORMATION Samina Qureshi, M.D. PSI INTERNATIONAL Inc.

Combination products The paradigm shift

Waiving Target Animal Batch Safety Testing for vaccines

Patient Involvement in the Development and Safe Use of

Dr Manisha Shridhar Regional Advisor WHO-SEARO

Presentation transcript:

ISO/HL Specification: Individual Case Safety Report (ICSR) Release 2 Lise Stevens Data Standards Project Manager FDA CBER/ADRM Bioinformatics Support Staff April 10, 2012

2 Discussion Topics  Overview of the ISO/HL Specification  ICH Conformance Profile  FDA Adoption, Testing and Implementation

3 ISO/HL Multi-part international standard for AE reporting: (Part 1) is an over-archiving reporting specification for adverse event (AE), product problem and consumer complaint reporting (Part 2) is a conformance profile for human pharmaceuticals reporting between regulated industry and regulators

4 ISO/HL Over-archiving specification that supports: AE, product problem and consumer complaint reporting for all FDA regulated products Harmonized 2008 requirements from international standards setting groups: ICH E2B, VICH, GHTF Additional requirements harmonized with HL7 Patient Safety Workgroup

5 ISO/HL ISO implementation conformance profile based upon: Updated ICH E2B(M) reporting guideline ICH regional requirements: EU, Japan and US

6 ISO/HL Accepted by HL7 as Normative Standard September 2010 Finalized as an ISO International Standard as of December 2011 Accepted by the American National Standards Institute January 2012

7 ICH Conformance Profile ISO/HL is a conformance profile that will replace ICH E2B(M) New specification supports: Adoption and implementation consistency ICH “core” reporting requirements specified in ICH E2B(R3) guideline (XML schema, data elements and vocabulary) Regional reporting requirements ICH regulators will issue additional reporting guidance as regional appendices

8 FDA Adoption CDRH adopted the HL7 ICSR Release 1 specification for its electronic medical devices reporting program (eMDR) in 2006 CVM pre-adopted ICSR Release 2 in 2010 to support electronic animal drug AE reporting from industry based upon VICH Guideline (GL 42) CBER began implementation planning in 2011 to support electronic vaccine AE reporting from industry in support of new regulation for mandatory electronic submission of postmarket AEs

9 CBER Testing and Implementation Goal is to remain consistent with ICH guidance, but extend or make use of additional XML schema tags to accommodate vaccine requirements

10 VAERS and ICH E2B XML Example ` Component section for VAERS Box 18 Component section for VAERS Box 19 and ICH E2B B.1.7.1

11 CBER Testing and Implementation Phase I covers electronic vaccine reporting from industry based upon the ICH conformance profile and VAERS-1 form Goal is to support a phased development and implementation to support all CBER-regulated products: Phase I: Vaccines FY 2012 Phase II: CBER ANDA, BLA, NDAs: e.g., Blood components, including Fatalities, Blood Bags, Plasma Expanders FY 2013 Phase III: CBER-regulated devices FY 2014

12 CBER Pilot Testing Working with contractors to enhance FDA tools: Pragmatic Data XFORM: Expands 2010 pilot BAH eSubmitter:  Leverages CDRH eMDR development  Expands CDER version to support VAERS-1 and updated E2B specification Anticipate UAT testing: Summer 2012

13 CBER Implementation Goal is to be ready to receive production submissions to support new regulation: Currently working on CBER infrastructure enhancements Already identified changes to industry guidance Companies have 1 year to comply with rule Do not anticipate approval of waivers Expect to have draft guidance ready for FDA General Counsel review when ICH Step 4 Guideline is signed November 2012

14 Acronyms ANDA = Abbreviated New Drug Application BAH = Booz, Allen and Hamilton BLA = Biologics License Application CBER = Center for Biologics Evaluation and Research CDER = Center for Drug Evaluation and Research CDRH = Center for Devices and Radiological Health CVM = Center for Veterinary Medicine EU = Europe FDA = Food and Drug Administration GHFT = Global Harmonization Task Force (Devices) HL7 = Health Level Seven ICH = International Conference on Harmonisation ISO = International Standards Organization NDA = New Drug Application UAT = User Acceptance Testing US = United States VICH = Veterinary International Conference on Harmonisation XML = Extensible Markup Language